The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $152.57, a high ...

H.C. Wainwright lowered the firm’s price target on BioNTech (BNTX) to $145 from $150 and keeps a Buy rating on the shares. The firm says ...

BioNTech has shown why it made small cell lung cancer (SCLC) a priority for its PD-L1xVEGF-A bispecific. | BioNTech has shown ...

BioNTech SE (NASDAQ:BNTX – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the eighteen brokerages that are covering the company, MarketBeat.com reports. Three research ...

(Reuters) -German COVID-19 vaccine maker BioNTech on Monday said that its 2025 revenues would likely fall to between 1.7 billion euros ($1.85 billion) and 2.2 billion euros, prompting a decline in its ...

Shares in Moderna, Vaxcyte, Novavax and BioNTech all fell Monday after Peter Marks, head of the FDA office that reviews ...

BNT327, a PD L1/VEGF antibody, belongs to a class of next-generation immunotherapies hoping to beat out Keytruda.

BioNTech has passed on Autolus Therapeutics’ dual targeting CAR-T cell therapy. One year after securing a chance to ...

Truist Financial analyst Asthika Goonewardene maintained a Buy rating on BioNTech SE (BNTX – Research Report) today. The company’s shares ...

The general mood among these heavyweight investors is divided, with 25% leaning bullish and 62% bearish. Among these notable ...

In a legal battle between BioNTech and CureVac, the European Patent Office declared a patent owned by CureVac ...

Shares of CureVac climbed after the European Patent Office confirmed the validity of a patent that has been the subject of a lawsuit filed by BioNTech. The stock rose 7% to $2.99 on Friday. Shares ...